Does Insurance Cover GeneSight Testing? Costs, Denials, and Appeals

Most major insurance plans do cover GeneSight testing, but only when your prescriber documents that the result will guide a specific medication decision and your plan’s prior authorization steps are followed. If your insurer pays nothing, GeneSight caps the self-pay price at $330, and income-based assistance can bring that down to $0, $100, or $200 for patients who qualify.

What Insurers Require Before They’ll Pay

Insurance companies evaluate GeneSight claims against medical necessity criteria, and simply having a psychiatric diagnosis is not enough. Your prescriber needs to show that the test result will directly inform a medication decision already on the table. Most insurers want to see that your doctor has a specific drug in mind, or is already prescribing one, that has a known gene-drug interaction, and that knowing your genetic profile would change the plan.

Each plan publishes its own medical policy, usually on the insurer’s website or available by calling customer service. That document spells out which diagnoses qualify, what documentation is needed, and whether the test must be ordered by a psychiatrist rather than a primary care provider. Some plans classify GeneSight as experimental or investigational, which effectively blocks coverage no matter how strong the clinical case.

Even plans that cover pharmacogenomic testing may impose limits. Some restrict the test to once per lifetime. Others require that you’ve already tried and failed at least one medication before the test is considered justified. Reading your plan’s specific policy before the sample is collected saves you from an unpleasant surprise on the bill.

Preauthorization

Many plans require preauthorization. That means the insurer must approve the test before it’s performed, and skipping the step is one of the easiest ways to get stuck with the full bill. Your prescribing physician submits clinical documentation: your diagnosis, the medications you’ve previously tried and how you responded, and an explanation of why genetic testing would inform the next treatment decision. Review can take anywhere from a few days to a few weeks. Some insurers offer expedited review for urgent cases, but your doctor usually needs to request it specifically.

If preauthorization is granted, the insurer issues an approval number that must appear on the claim. Keep a copy. Approval doesn’t guarantee full coverage — you’ll still owe any applicable deductible, copay, or coinsurance — and most approvals expire within a set window, so schedule the test promptly.

Medicare, Medicaid, and VA Coverage

Medicare

Medicare covers pharmacogenomic testing under Local Coverage Determination L38294, but the criteria are narrower than many patients expect. The test is reasonable and necessary only when your doctor has already narrowed treatment to a specific medication with a known actionable gene-drug interaction recognized by the FDA or CPIC guidelines. Medicare explicitly states that testing is not covered simply because you have a particular diagnosis; the prescriber must document that genetic results are needed to safely administer or dose the drug being considered.1Centers for Medicare & Medicaid Services. LCD – MolDX: Pharmacogenomics Testing (L38294)

In practice, your psychiatrist needs to document which medication they’re considering, why that medication has a relevant gene-drug interaction, and how the result will affect prescribing. Claims using a neuropsychiatric panel must include the appropriate diagnosis codes.2Centers for Medicare & Medicaid Services. Billing and Coding: MolDX: Pharmacogenomics Testing (A58395) Missing any of these pieces is where most Medicare denials originate.

Medicaid

Medicaid coverage varies widely by state. Research suggests fewer than one in five state Medicaid programs have specific policies addressing pharmacogenetic testing, and those that do may limit coverage to certain clinical scenarios. Contact your managed care plan directly to ask whether pharmacogenomic testing is a covered benefit and what prior authorization applies.

VA Benefits

The Department of Veterans Affairs offers pharmacogenomic testing through its healthcare system to help providers find medications or doses better suited to individual patients and reduce side effects. Veterans interested in testing should contact their primary care provider to discuss eligibility.3Veterans Affairs. Pharmacogenomic Testing For Medications

In-Network Labs and Surprise Billing

GeneSight samples are processed by Myriad Genetics’ lab, and your costs depend heavily on whether that lab is in-network with your plan. When the lab is in-network, your insurer pays its negotiated rate and you owe only your normal cost-sharing. When the lab is out-of-network, the insurer may reimburse at a much lower rate or refuse to pay at all, leaving you with a significantly larger bill.

Before your provider orders the test, call your insurer and confirm the processing lab’s network status. Some plans maintain preferred lab lists for genetic testing, and using the wrong lab can mean the difference between a modest copay and the full sticker price. If no in-network option exists, ask about a gap exception or single-case agreement, which can sometimes get out-of-network services covered at in-network rates. Get any such agreement in writing before the test is processed.

Federal law offers some protection. Under the No Surprises Act, if you receive lab services at an in-network facility, out-of-network lab providers generally cannot balance bill you beyond your plan’s in-network cost-sharing amount for pathology and laboratory services. If you’re sent to a standalone out-of-network lab, those protections may not apply, which is another reason to verify network status upfront.

Why Claims Get Denied

Even with preauthorization, claims can be denied. The common reasons are:

  • Not medically necessary. The documentation didn’t clearly connect the test to a specific prescribing decision, or your plan’s policy excludes your diagnosis.
  • Experimental or investigational classification. Some insurers don’t consider pharmacogenomic panel testing a proven standard of care.
  • Coding errors. Claims require specific procedure codes such as CPT 81225 for CYP2C19 analysis or 81226 for CYP2D6. Wrong codes, or unlisted codes submitted without supporting documentation, can trigger a technical denial.
  • Missing preauthorization. If your plan required prior approval and it wasn’t obtained, the insurer can deny regardless of medical necessity.
  • Insufficient documentation. The prescriber’s notes don’t adequately describe prior treatment failures, the medication under consideration, or how the result would change the plan.

Most of these are fixable. Coding errors can be corrected and resubmitted. Documentation gaps can be filled with a supplemental letter from your psychiatrist. Even medical necessity denials can be overturned on appeal with stronger clinical evidence.

How to Appeal

Your insurer must send an Explanation of Benefits or denial letter stating the reason. Read it carefully, because the appeal strategy depends on why the claim was rejected.

The first step is an internal appeal. Your prescribing physician typically prepares a written appeal addressing the specific denial reason. For a medical necessity denial, include a detailed treatment history, an explanation of why the test was clinically indicated, and peer-reviewed research supporting pharmacogenomic testing for your condition. For a coding error, the lab may simply resubmit with corrected codes. Most plans allow at least 180 days from the denial notice to file an internal appeal.4Centers for Medicare & Medicaid Services. External Appeals

If the internal appeal fails, some insurers offer a second-level review, which may involve a different reviewer or a peer-to-peer conversation between your prescriber and the insurer’s medical director. These can be effective when the original denial came from a reviewer unfamiliar with psychiatric pharmacogenomics.

When internal options are exhausted, you have the right to an external review by an independent third party. Under the Affordable Care Act, insurers must allow external appeals for denied medical services, and you generally have four months from the final internal denial to request one.5eCFR. 45 CFR 147.136 – Internal Claims and Appeals and External Review Processes If the external reviewer sides with you, the insurer must cover the test. Your state’s insurance department can help if you hit roadblocks.

What You’ll Actually Pay

With Insurance

Even when your plan covers GeneSight, you’ll likely owe something out of pocket. If you haven’t met your annual deductible, the negotiated cost applies toward it. Once the deductible is satisfied, you’d pay your plan’s coinsurance percentage or a flat copay, depending on how lab benefits are structured. With a high-deductible plan, the full negotiated rate could apply early in the year before the deductible is met.

The $330 Cap

Regardless of your insurance situation, GeneSight caps patient costs at $330 through what it calls the GeneSight Promise. If you’re uninsured, choose to self-pay, or your cost-sharing would exceed $330, you can take the $330 flat rate. GeneSight commits to contacting you before processing the test if your estimated cost would exceed that amount, giving you the option to choose self-pay or cancel.6GeneSight. Genetic Testing Cost

For patients who can’t afford $330, GeneSight offers income-based financial assistance that can reduce the cost to $0, $100, or $200 depending on household size and income relative to federal poverty guidelines. As a rough guide for 2026, a single person earning under approximately $16,000 would owe nothing, and a household of four earning under about $33,000 would also qualify for the $0 tier.7HHS ASPE. 2026 Poverty Guidelines Higher incomes qualify for progressively higher but still discounted costs. If your out-of-pocket amount is $100 or more, an interest-free payment plan lets you spread payments over up to 12 months.6GeneSight. Genetic Testing Cost

One important catch. Patients with federally funded insurance, including Medicare, Medicare Advantage, Medicaid, TRICARE, and VA coverage, are not eligible for GeneSight’s financial assistance program due to federal anti-kickback regulations.8GeneSight. Financial Information for the GeneSight Test If you have one of these plans and your claim is denied, you would need to win an appeal or pay out of pocket at the $330 self-pay rate.

HSA and FSA Funds

Pharmacogenomic testing ordered to guide medical treatment generally qualifies as an eligible expense under health savings accounts and flexible spending accounts. You can use those pre-tax funds to cover your share, whether that’s a copay, deductible payment, or the full self-pay price.

Can Taking the Test Affect Your Health Coverage?

The Genetic Information Nondiscrimination Act (GINA) prohibits health insurers from using genetic information to make coverage, underwriting, or premium-setting decisions. Insurers also cannot require you to take a genetic test or provide genetic information as a condition of coverage.9National Human Genome Research Institute. Genetic Discrimination GINA does not extend to life insurance, disability insurance, or long-term care insurance, but for health coverage your GeneSight results cannot be held against you.